Fetal medicine is an upcoming branch of Obstetrics where the fetus is given the primary care right from screening to diagnosis and management of a fetal problem. Read more at http://bangalorefetalmedicine.com/
Part 1 of the introduction to the Womb Twin Survivors Research Project. Explaining what a womb twin survivor is. Womb twin survivors are the sole survivors of a twin or multiple pregnancy. Their twin died in the womb or around birth and this includes the "vanishing twin" pregnancies. Various signs are explained, first during the pregnancy, then at the birth and finally inside the body of the survivor, which includes a dermoid cyst and a teratoma.
Fetal medicine is an upcoming branch of Obstetrics where the fetus is given the primary care right from screening to diagnosis and management of a fetal problem. Read more at http://bangalorefetalmedicine.com/
Part 1 of the introduction to the Womb Twin Survivors Research Project. Explaining what a womb twin survivor is. Womb twin survivors are the sole survivors of a twin or multiple pregnancy. Their twin died in the womb or around birth and this includes the "vanishing twin" pregnancies. Various signs are explained, first during the pregnancy, then at the birth and finally inside the body of the survivor, which includes a dermoid cyst and a teratoma.
Oral communication in the Fetal Medicine Foundation World Congress, june 2013. Description of the results in our hospital after 20 years of selective embryo-fetal reduction. Factors affecting outcome.
North Thames Children's Cancer Network Coordinating GroupUCLPartners
Presentation by Darren Hargrave, Co-Chair of the North Thames Children's Cancer Network Coordinating Group at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Prenatal Genetic Screening with VarSeqGolden Helix
Our past webcast explored the current approaches for screening and diagnosis of genetic disorders in prenatal testing. While the methods available at the time were robust, they were severely limited, creating a need for a higher diagnostic yield and more efficient analysis for a wider range of genetic tests. The solution proposed was to improve and simplify prenatal screening and diagnosis with whole exome sequencing (WES).
During that webcast, we highlighted the advantages of WES over traditional methods such as karyotyping and chromosomal microarray, including improved accuracy, granularity, and cost-effectiveness. We also emphasized the potential of WES to expand diagnosis for many other adverse maternal-fetal complications beyond the large aneuploidy events previously covered. However, there was still an intimidation factor when it came to the massive data output from the exome. Fortunately, Golden Helix provided the necessary tools to build and standardize these genetic assays, simplifying the analytical process while leveraging increased diagnostic output. We explored our VarSeq software to demonstrate some example workflows of cases positive for Trisomy 21, an exon loss in DMD related to Duchenne Muscular Dystrophy, and detection of a single base change resulting in a LOF variant in RUNX1 relevant to hereditary leukemia.
Our goal was to expose our viewers to the methods of conquering this vast NGS-based data and play a role in dissolving any feeling of intimidation. Overall, exome sequencing has the potential to vastly improve diagnostic outcomes and widen discoveries in the research related to prenatal testing, and Golden Helix products are designed to facilitate this process.
NHSIQ hosted a meeting of Strategic Clinical Network Cardiac Leads on Wednesday 2nd July in London. Discussions covered making best use of data with NCVIN and NICOR, also the development of a cardiac data dashboard. The group looked at how to integrate local and national SCN priorities. The British Heart Foundation came to talk about the work of national and regional teams including the exciting new resource including ‘innovation in practice’ which supports of evidencing and implementation of good practice case studies.
Oral communication in the Fetal Medicine Foundation World Congress, june 2013. Description of the results in our hospital after 20 years of selective embryo-fetal reduction. Factors affecting outcome.
North Thames Children's Cancer Network Coordinating GroupUCLPartners
Presentation by Darren Hargrave, Co-Chair of the North Thames Children's Cancer Network Coordinating Group at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Prenatal Genetic Screening with VarSeqGolden Helix
Our past webcast explored the current approaches for screening and diagnosis of genetic disorders in prenatal testing. While the methods available at the time were robust, they were severely limited, creating a need for a higher diagnostic yield and more efficient analysis for a wider range of genetic tests. The solution proposed was to improve and simplify prenatal screening and diagnosis with whole exome sequencing (WES).
During that webcast, we highlighted the advantages of WES over traditional methods such as karyotyping and chromosomal microarray, including improved accuracy, granularity, and cost-effectiveness. We also emphasized the potential of WES to expand diagnosis for many other adverse maternal-fetal complications beyond the large aneuploidy events previously covered. However, there was still an intimidation factor when it came to the massive data output from the exome. Fortunately, Golden Helix provided the necessary tools to build and standardize these genetic assays, simplifying the analytical process while leveraging increased diagnostic output. We explored our VarSeq software to demonstrate some example workflows of cases positive for Trisomy 21, an exon loss in DMD related to Duchenne Muscular Dystrophy, and detection of a single base change resulting in a LOF variant in RUNX1 relevant to hereditary leukemia.
Our goal was to expose our viewers to the methods of conquering this vast NGS-based data and play a role in dissolving any feeling of intimidation. Overall, exome sequencing has the potential to vastly improve diagnostic outcomes and widen discoveries in the research related to prenatal testing, and Golden Helix products are designed to facilitate this process.
NHSIQ hosted a meeting of Strategic Clinical Network Cardiac Leads on Wednesday 2nd July in London. Discussions covered making best use of data with NCVIN and NICOR, also the development of a cardiac data dashboard. The group looked at how to integrate local and national SCN priorities. The British Heart Foundation came to talk about the work of national and regional teams including the exciting new resource including ‘innovation in practice’ which supports of evidencing and implementation of good practice case studies.
Stroke prevention services - quality & safety indicatorsHelicon Health
Prof David Patterson, Consultant Cardiologist, Professor of Cardiovascular Medicine and CEO of Helicon Health, gave this presentation at Commissioning Live - November 2014. He covers a range of issues including better identification of patients with atrial fibrillation and better management of anticoagulation patients.
Helicon Health's web-based integrated package - HeliconHeart - is compliant with National Institute for Health and Care Excellence (NICE) guidelines on anticoagulation and self-monitoring, and cited as a learning exemplar in NICE’s guidelines for atrial fibrillation.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
1. NNFM
Nordic
Network
-‐
Fetal
Medicine
April
14
-‐
2015
Gothenburg
Invasive
Fetal
Medicine
A
workshop
on
Nordic
collabora7on
in
invasive
fetal
medicine
–
supported
by
Nordic
Council
2. Challanges
within
invasive
fetal
medicine
and
fetal
therapy
!
Rare
condiEons
-‐
how
to
gain
rouEne
Low
cases
load
–
paHern
recogniEon
may
fail
Training
on
paEents
can
be
fatal
for
the
fetus
Decreasing
numbers
of
CVS
aMer
NIPT
Cut
down’s
by
hospital
owners
!
3. AIM
of
today
!
To
create
collabora7on
across
our
Nordic
borders
hopefully
resul7ng
–
along
the
way
-‐
in
improvements
for
our
pregnant
women
and
pa7ents
by
establishing
networks
for
educa7on
and
competence
development
for
doctors
working
within
invasive
fetal
medicine.
4. The
funding
by
Nordic
Council
ApplicaEon:
Send
January
2014,
concerning
the
establishment
of
a
Nordic
collaboraEon
within
competence
development
in
the
invasive
part
of
the
fetal
medicine
-‐
NO
responce
!
200.000,-‐D.kr.
oktober
2014
–
very
suddenly
More
funding
will
depend
on:
Establishings
las7ng
agreements
between
our
Nordic
departments
5. The
funding
by
Nordic
Council
200.000,-‐
D.
Kr.
for
this
meeEng
to
cover:
accomodaEon
transports
foods
and
meeEng
faciliEes
ect.
43
parEcipants
today
19
applied
for
funding
KS
responsible
for
accounEng
in
details
can
be
transported
to
next
year/
or
returned
NC
has
encouraged
us
to
apply
for
a
next
meeEng/conference
in
2016
.
More
funding
will
depend
on:
Establishings
las7ng
agreements
between
our
Nordic
departments
6. VIP
message
All
details
for
reimbursement
through
Karin
–
must
be
filled
out
TODAY
–
and
all
reciepts
possible
passed
on
to
Karin
!!
Karin
will
pay
the
hotel
directly
at
check
out
Thursday
-‐
before
for
those
who
need
it.
7. Tuesday April 14th
A workshop on Nordic collaboration in invasive fetal medicine – supported by Nordic Council
Moderators: Karin Sundberg – Rigshospitalet Copenhagen
Peter Lindgren – Karolinska Stockholm
11.00-11.15 am
- Welcome to NNFM by Bo Jacobsson, Sahlgrenska Gothenburg.
– Introduction: Karin Sundberg (DK) and Peter Lindgren (SE).
11.15-11.35 am – Invasive Fetal Medicine – organisation Denmark, Karin Sundberg.
11.35-12.10 am – Invasive Fetal Medicine – organisation Sweden, Peter Lindgren.
12.10-12.30 pm – Invasive Fetal Medicine – organisation Norway, Torbjørn Eggebø.
12.30-13.30 pm Lunch
13.30 – 13.50 pm – Invasive Fetal Medicine – organisation Finland, Aydin Tekay.
13.50 – 14.05 pm – Invasive Fetal Medicine – organisation Iceland, Hildur Hardardottir.
14.05 – 14.15 pm – Overview Nordic countries – Olav Bjørn Petersen – Århus-DK.
14.15 – 14.45 pm Fetal aortic valvuloplasty, Mats Mellander (SE)
14.45 – 15.45 pm
Coffee/cake in smaller work shop groups of mixed nationalities
Brainstorm concerning future potential collaboration fields,
including competence development of Nordic doctors in invasive fetal medicine.
15.45 – 16.00 pm Break
16.00 – 16.45 pm
Reporting by the groups and discussion of proposed ideas and eventual constitution
of a stearing group on invasive competence development under NNFM.
16.45 – 17.00 pm
Conclusions, Karin Sundberg (DK) and Peter Lindgren (SE)
19.00 pm
Dinner at the Clarion Hotel Post
8. 8
DENMARK
Invasive Fetal Medicin – Organisation
by Karin Sundberg
Fetal Medicine Dept. Rigshospitalet - Copenhagen
9. Denmark
-‐
demographics
• 5,6
mill
inhabitants
• Public
health
care
system
• 55-‐60.000
deliveries/year
• 21
obstetric
departments
• ”All”
deliveries
take
place
in
public
hospitals
• 99%
of
the
prenatal
care
in
public
hospitals
• >
95%
aHend
1.
trimester
T
21
screening
Føtodatabasen
–
Astraia
DFMS
–
Dansk
Føtalmedicinsk
Selskab
9
10. 10
Danish
naEonal
guideline
2004
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6
Detectionrate(%)
False-positive rate (%)
Random
Maternal age
Triple test
PAPP-A + β-hCG
NT
NT and PAPP-A+ β-hCG
11. • Postnatal
versus
prenatal
T21
diagnosis
Danish
T21
Dansk
CytogeneEsk
Centralregister
0
20
40
60
80
100
120
140
160
180
number
year
postnatal
prenatal
12. 12
Postnatally
diagnosed
with
T21
Danish
CytogeneEc
Register
0
10
20
30
40
50
60
70
number
year
postnatal
2013
births
not
completed
13. Yearly
number
of
invasive
test
(AC
+
CVS)
13
Invasive
tests
-‐
significantly
decreased
Danish
CytogeneEc
Register
0
1000
2000
3000
4000
5000
6000
7000
8000
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
number
year
14. 14
Change
in
type
of
invasive
tests
0
500
1000
1500
2000
2500
3000
3500
4000
4500
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
Number
Year
AC
CVS
Danish
CytogeneEc
Register
15. CVS
–
Amniocentesis
in
Denmark
Undertaken
at
16
departments
in
Denmark
–
some
do
less
than
100/year
!!!
Greenland
and
Faroe
Islands
only
do
Amniocentesis.
BIG
PROBLEM
for
educaEon
and
competence
maintainance
!!
Quality
sEll
good
–
all
use
same
TA
technique
and
needleguide
–
very
low
naEonal
spontaneous
aborEon
rate
Future
quality
?
16. Centralised
invasive
procedures
in
Denmark
to
Rigshospitalet
Intrauterine
blood
transfusions
–
all
(15
to
34
weeks)
Intrauterine
therapeu7c
drains
thorax
–
”bladder”
Treatment
of
TTTS
–
by
laser
or
cord
occlusion
(16-‐24
weeks)
Complicated
monochorionic
cases
twin/triplets
op7ng
for
selec7ve
fe7cide
by
cord
occlusion
/
radiofrequency
abla7on
(resent).
18. Invasive
procedures
at
the
4
larger
university
hospitals
in
Denmark
Fetal
reduc7ons
-‐1.
trimester
Selec7ve
fe7cides
-‐
discrepancy
19. Centralised
invasive
procedures
in
Denmark
to
Rigshospitalet
Our
invasive
team
is
presently:
Lisa
Neerup
Jensen,
Kirsten
Søgaard
and
Karin
Sundberg
Can
be
contacted
on
0045
35
45
08
77
We
receive
paEents
from
all
other
Nordic
Countries
–
referred
from
public
hospitals
second
opinion
or
for
invasive
treatment
.
A
tradiEon
started
by
Connie
Jørgensen
–
Head
of
Department
unEl
2012
–
leO
us
for
Malmoe-‐
is
now
head
of
Emma
Klinikken
!
20. Danish
organisa7on
–
legal
termina7ons
!
Free
aborEon
unEl
12+0
week
for
persons
on
Danish
ground
gestaEonal
age
determinated
by
CRL
or
LMP
AMer
12+0
weeks
up
to
22+0
weeks
The
regional
aborEon
council
is
applied
by
the
MD
in
charge
!
Five
regionale
councils
cover
the
country
Level
of
severity
evaluated
–
consistency!!!
Each
aborEon
council
has
3
members:
A
MD
in
OB/GYN,
A
person
from
the
social
authoriEes
A
psyciatrist
In
simple
cases
usually
by
phone
-‐
answer
within
24
hours
If
terminaEon
is
denied
–
the
paEent
can
appeal
to
the
superior
NaEonal
aborEon
appeal
council
of
3
persons
too
regulated
by
The
NaEonal
Health
Authority
-‐
SST.
ExcepEons
–
only
for
lethal
condiEons
or
severe
maternal
health
issues.